ArticleFrontiers in medicine2024
Disease burden and trends of lung cancer attributable to nickel among Chinese and global population: a cross-sectional study.
Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nickel is a well-established carcinogen, and China stands as a significant producer of nickel compounds. Nickel-associated lung cancer is increasingly acknowledged as a pressing public health concern. This study presents a comprehensive analysis at temporal, spatial, and population levels utilizing the most recent data from GBD 2019 to estimate the disease burden of nickel-associated lung cancer from 1990 to 2019, and make predictions to 2035. Methods: We delineated data on nickel-associated lung cancer concerning mortality, disability-adjusted life years (DALY), and age-standardized rates (ASRs) over a 30-year period based on the global burden of disease (GBD) 2019. Joinpoint regression analysis was utilized to identify temporal changes and to estimate the annual percentage change (APC) as well as the average annual percentage change (AAPC) for each trend segment. The Nordpred model was employed to elaborate on ASRs trends from 1990 to 2019, along with projections for the subsequent 15 years. Results: In both China and globally, the mortality rate from nickel-associated lung cancer and the associated DALYs have increased by 145.8, 77.8, 120.2, and 64.6%, respectively. ASRs within Chinese and global populations exhibit a pattern characterized by an initial increase followed by a decrease as age progresses, with males higher than females. The trend for DALY indicates an initial rise followed by a decline, peaking in the year 2027. Conclusion: The age structure of nickel-associated lung cancer patients shows an aging trend, and the ASDR in the Chinese population indicates a potential upward trend when projecting the disease burden of nickel-associated lung cancer over the next 15 years. We should place greater emphasis on the implementation of preventive strategies and the enhancement of the quality of life for current sufferers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.